Navigating the GLP-1 Wild West: A Conversation With Dr. Vin Gupta

Are you getting a GLP-1 prescription from someone who's never examined you?Dr. Vin Gupta, pulmonologist and former Chief Medical Officer at Amazon, joins Dr. Cooper to expose the dangerous gap between legitimate obesity medicine and the unregulated direct-to-consumer market. This conversation reveals why proper medical evaluation matters and how profit-driven platforms are exploiting desperate patients.KEY TAKEAWAYSGLP-1 medications require individualized medical evaluation, not one-size-fits-all prescribingDirect-to-consumer microdosing platforms lack FDA approval and proper medical oversightThe erosion of trust in healthcare has created opportunities for unregulated treatmentsComprehensive metabolic care includes regular lab work, body composition monitoring, and personalized treatment plansTechnology should enhance medical care, not replace proper physician evaluationNOTABLE QUOTE"I see so many people that come in, you know, they're obsessed with monitoring their HRV, their heart rate variability, and yet they had no idea they have pre-diabetes and they had no idea that they have triglyceride levels through the roof." — Dr. Emily CooperGUEST BIODr. Vin Gupta is a pulmonologist, public health expert, and medical analyst for NBC News. He served as Chief Medical Officer at Amazon and has dedicated his career to translating complex science into actionable health insights at both individual and population levels.GLOSSARYGLP-1 medications: Glucagon-like peptide-1 receptor agonists, medications that help regulate blood sugar and appetite, including brand names like Ozempic, Wegovy, and ZepboundMicrodosing: Taking smaller amounts of medication than officially prescribed or approvedDirect-to-consumer (D2C): Healthcare services that bypass traditional medical settings, often delivered through apps or online platformsHRV: Heart rate variability, a measurement of the variation in time between heartbeatsPre-diabetes: Blood sugar levels that are higher than normal but not high enough to be diagnosed as type 2 diabetesLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: [email protected] or [email protected] Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.